卡瑞利珠单抗联合替吉奥治疗转移性食管癌的临床疗效比较

Comparison of Clinical Efficacy of Camrelizumab Combined with Tegafur/Gimeracil/Oteracil Potassium in the Treatment of Metastatic Esophageal Cancer

摘要

目的:观察卡瑞利珠单抗联合替吉奥胶囊在转移性食管癌维持治疗中的疗效和安全性。方法:将2019年1月-2021年11月宜昌市中心人民医院收治的86例转移性食管癌患者,按随机数字表法分为接受卡瑞利珠单抗联合替吉奥胶囊治疗的观察组(n=42)和替吉奥胶囊治疗的对照组(n=44),治疗2个周期后评价两组患者临床疗效及不良反应。结果:与对照组相比,观察组患者疾病控制率(88.10% vs 54.55%)和临床受益反应率(80.95% vs 56.82%)显著升高,中位无进展生存期(8.50个月vs 5.90个月)、中位总生存期(17.70个月vs 10.70个月)均显著延长(均P<0.05)。在1年PFS和1年 OS人群中,两组患者PD-L1阳性和 PD-L1阴性的人数均无明显差异(均P>0.05)。观察组Ⅰ-Ⅱ级骨髓抑制(66.67% vs 4.55%)、手足综合征(38.10% vs 2.27%)、口腔炎(59.52% vs 11.36%)、食欲减退(42.86% vs 15.91%)等不良反应发生率明显高于对照组(均P<0.05)。结论:卡瑞利珠单抗联合替吉奥胶囊可有效提高转移性食管癌患者的治疗效果,但需密切注意不良反应发生情况。

Abstract

Objective: To observe the efficacy and safety of camrelizumab combined with tegafur/gimeracil/oteracil potassium in the maintenance treatment of metastatic esophageal cancer. Methods: A total of 86 patients with metastatic esophageal cancer admitted to Yichang Central People's Hospital from January 2019 to November 2021 were divided into an observation group (n=42) receiving camrelizumab combined with tegafur/gimeracil/oteracil potassium and a control group (n=44) receiving tegafur/gimeracil/oteracil potassium according to the random number table method. After 2 cycles of treatment, the clinical efficacy and adverse reactions of the two groups were evaluated. Results: Compared with the control group, the disease control rate (88.10% vs 54.55%) and the clinical benefit response rate (80.95% vs 56.82%) were significantly increased, and the median progression free survival (8.50 months vs 5.90 months) and the median overall survival (17.70 months vs 10.70 months) were significantly prolonged (all P<0.05).There was no significant differfence in the PD-L1 positive and negative between two goups in the 1-year PFS and 1-year OS population. The incidences of grade Ⅰ-Ⅱ myelosuppression (66.67% vs 4.55%), hand-foot syndrome (38.10% vs 2.27%), stomatitis (59.52% vs 11.36%), and anorexia (42.86% vs 15.91%) in the observation group were significantly higher than those in the control group (all P <0.05). Conclusion: Camrelizumab combined with tegafur/gimeracil/oteracil potassium can effectively improve the treatment effect of patients with metastatic esophageal cancer, but close attention should be paid to the occurrence of adverse reactions.

关键词

卡瑞利珠单抗 / 替吉奥胶囊 / 转移性食管癌

Key words

camrelizumab / tegafur/gimeracil/oteracil potassium / metastatic esophageal cancer

参考文献

[1] Chen R, Zheng R S, Zhang S W, et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data[J]. J Natl Cancer Cent, 2023, 3(1): 21-27.

[2] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[3] Zeng H M, Chen W Q, Zheng R S, et al. Changing cancer survival in China during 2003—15: a pooled analysis of 17 population—based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.

[4] Jiang D M, Sim H W, Espin—Garcia O, et al. Chemoradiotherapy using carboplatin plus paclitaxel versus cisplatin plus fluorouracil for esophageal or gastroesophageal junction cancer[J]. Oncology, 2021, 99(1): 49-56.

[5] Huang J, Xu J M, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second—line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open—label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842.

[6] Wu S S, Luo H Q, Chen W J, et al. Camrelizumab combined with apatinib plus irinotecan as a second—line treatment in advanced or metastatic esophageal squamous cell carcinoma patients[J]. BMC Cancer, 2025, 25(1): 845.

[7] Wang M X, Wei D D, Cui Z, et al. Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma[J]. J Thorac Dis, 2025, 17(3): 1711-1722.

[8] Lu Z H, Sun G P, Li J C, et al. Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies[J]. Cancer Immunol Immunother, 2025, 74(4): 138.

[9] Oishi R, Kobayashi S, Nagashima S, et al. Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study[J]. BMC Cancer, 2025, 25(1): 653.

[10] Lu J L, Lei Y Y, Mo Y Y, et al. Pharmacokinetics and bioequivalence of two formulations of the S—1 (tegafur/gimeracil/oxonate) capsule in Chinese cancer patients under fasting and fed conditions: a multicenter, randomized, open—label, single—dose, double—cycle crossover study[J]. Front Pharmacol, 2025, 16: 1494902.

[11] Kobayashi K, Einama T, Miyata Y, et al. Prognostic impact of dose reduced S—1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study[J]. Int J Clin Oncol, 2025, 30(6): 1218-1228.

[12] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.

[13] Wang R X, Liu S L, Chen B Q, et al. Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Cancers, 2022, 14(20): 5168.

[14] Kasi P M, Grothey A. Chemotherapy maintenance[J]. Cancer J, 2016, 22(3): 199-204.

[15] Kakeji Y, Oshikiri T, Takiguchi G, et al. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy[J]. Esophagus, 2021, 18(1): 25-32.

[16] Wang R T, Wen S D, Du X Y, et al. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: a retrospective study[J]. Cancer Med, 2024, 13(17): e70228.

[17] Kang Y K, Chen L T, Ryu M H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2—negative, untreated, unresectable advanced or recurrent gastric or gastro—oesophageal junction cancer (ATTRACTION—4): a randomised, multicentre, double—blind, placebo—controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 234-247.

[18] Doki Y, Ajani J A, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous—cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462.

[19] Janjigian Y Y, Shitara K, Moehler M, et al. First—line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro—oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open—label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.

[20] Meng X R, Wu T, Hong Y G, et al. Camrelizumab plus apatinib as second—line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single—arm, open—label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 245-253.

[21] Lu Z H, Zhao J, Yang Z, et al. Effectiveness and safety of camrelizumab in advanced esophageal cancer: a prospective multicenter observational cohort studies (ESCORT—RWS)[J]. J Clin Oncol, 2023, 41(16_suppl): 4049.

[22] Mo D C, Huang J F, Luo P H, et al. Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: a meta—analysis of randomized controlled trials[J]. Medicine, 2022, 101(38): e30830.

[23] Li R Y, Huang B, Tian H, et al. Immune evasion in esophageal squamous cell cancer: from the perspective of tumor microenvironment[J]. Front Oncol, 2023, 12: 1096717.

[24] Chen Y, Zhu Z F, Zhao W X, et al. Long—term results of a phase 2 study of definitive chemoradiation therapy using S—1 for esophageal squamous cell carcinoma patients who were elderly or with serious comorbidities[J]. Front Oncol, 2022, 12: 839765.

[25] 孙静波, 宋丽杰, 李向柯, 等. 一线化疗后S—1维持治疗晚期食管癌的疗效[J]. 肿瘤, 2016, 36(6): 668-673.

[26] Nomura M, Yamaguchi T, Chin K, et al. Phase Ⅱ trial of adjuvant S—1 following neoadjuvant chemotherapy and surgery in patients with locally advanced esophageal squamous cell carcinoma: the PIECE trial[J]. Ann Surg Oncol, 2025, 32(1): 302-311.

[27] 陆元元, 丁文评. 替吉奥维持治疗一线化疗后无疾病进展晚期胃癌的 PSM 分析[J]. 吉林医药学院学报, 2025, 46(1): 33-37.

[28] Parsa H, Haji Maghsoudi L, Delghandi M. Evaluation of the risk factors of metastasis to central cervical lymph nodes in patients with papillary thyroid carcinoma[J]. Ann Med Surg, 2024, 86(7): 3847-3851.

[29] 阚璇. 替吉奥胶囊维持治疗晚期非小细胞肺癌的临床疗效[J]. 临床合理用药, 2023, 16(34): 8-11.

[30] 闫桂军, 杜海艳, 江红. 卡瑞利珠单抗联合替吉奥治疗晚期食管癌的临床疗效及安全性[J]. 癌症进展, 2024, 22(11): 11256-11259.

[31] Yap T A, Parkes E E, Peng W Y, et al. Development of immunotherapy combination strategies in cancer[J]. Cancer Discov, 2021, 11(6): 1368-1397.

基金资助

湖北省自然科学基金创新发展联合基金项目(2024AFD453)

宜昌市医疗卫生研究项目(A22-2-002)

宜昌市医疗卫生研究项目(B22-2-007)

宜昌市医疗卫生研究项目(A23-1-007)